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Recently, a high proportion of patients with late-stage
Trypanosoma brucei gambiense trypanosomiasis, who had
been treated with melarsoprol in some disease-endemic
areas, subsequently relapsed. To determine whether the
frequency of postmelarsoprol relapses increased over time,
we reviewed data from 2,221 trypanosomiasis patients
treated with melarsoprol during this period in Nioki,
Democratic Republic of Congo, from 1982 to 2001. The fre-
quency of relapses was 5.6%(31/553), 6.8%(35/512),
4.5%(18/398), 11.4%(34/299), and 5.0%(17/343) for those
treated from 1982 to 1985, 1986 to 1989, 1990 to 1993,
1994 to 1997, and 1998 to 2001, respectively. The higher
frequency of relapses in 1994 to 1997 was associated with
an incremental dosage regimen of melarsoprol. In multi-
variate analysis, after adjustment for treatment regimen,
sex, residence, and trypanosomes in cerebrospinal fluid,
postmelarsoprol relapses did not increase in Nioki, perhaps
because 1) little drug pressure exists; 2) subtherapeutic
doses have rarely been administered; 3) little potential
exists for the preferential transmission of melarsoprol-
resistant strains.
R
ecent reports suggest that the frequency of relapses
after melarsoprol treatment of late-stage Trypanosoma
brucei gambiense trypanosomiasis may be increasing, at
least in 3 foci where the frequency of postmelarsoprol
relapses is higher than the 5%–8% generally seen else-
where (1). In Ibbe, southern Sudan, 18%–20% of patients
treated with melarsoprol eventually relapsed (2,3), as did
27% of similar patients in the Arua focus of northwestern
Uganda (4). In M’banza Congo, northern Angola, 25% of
patients treated with melarsoprol had cerebrospinal fluid
(CSF) positive for parasites during treatment or relapsed
within 1 month (5). This development could have serious
implications for countries highly endemic for T.b. gambi-
ense trypanosomiasis (6,7). Eflornithine is the only alter-
native drug to melarsoprol for patients in late-stage
trypanosomiasis, generally defined by either the presence
of trypanosomes in the CSF, a CSF leukocyte count high-
er than 5/mm3, or both, but this drug needs to be adminis-
tered intravenously every 6 hours for 14 days, not an easy
task for rural hospitals with limited human and financial
resources.
An important question is whether rates of postmelarso-
prol relapses are indeed rising in these foci or merely
reflect a long-standing decrease in susceptibility to melar-
soprol of local strains, which became more obvious when
the incidence increased or when data collection and analy-
sis improved. Anecdotal reports have indicated that the fre-
quency of failures was 40% among patients treated with
melarsoprol in the early 1970s in the Kimpangu hospital of
Zaire (8). This hospital is located at the Angolan border,
and many of its patients came from northern Angola. In
Uganda and Sudan, no reports about rates of treatment fail-
ures have been published before these recent reports. In
Nioki, Democratic Republic of Congo (DRC), data have
been collected since 1982 on all patients in whom
Gambian trypanosomiasis was diagnosed. We thus
reviewed our database to determine whether secular
changes had occurred in the frequency of postmelarsoprol
relapses.
Methods
Nioki hospital, the only hospital of the district (popula-
tion ≈110,000), is located in the Bandundu Province of
DRC, at the confluence of the Mfimi and Molibampe
Rivers. Several trypanosomiasis foci are located on the
Mfimi River (inhabited by the Basakata) while others lie
on the Molibampe River (populated by the Bampe) or on
the road going north from Nioki (populated by the Baboma
and the Basengele). These 3 areas, as well as Nioki town
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All patients with T.b. gambiense trypanosomiasis treat-
ed in Nioki hospital from January 1, 1982, to December
31, 2001, were included in this observational study; fol-
low-up data were accumulated until December 31, 2003.
Most cases were diagnosed at Nioki hospital, while a
minority were referred by case-finding mobile teams or
rural health centers. Case-finding teams were active in the
1980s, collapsed around 1991 (9), and were reorganized on
a more modest scale later on. The vast majority of patients
lived within Nioki District, but case-patients from disease-
endemic villages outside the district have also been includ-
ed. The routine work-up of suspected case-patients
included a lymph node aspirate when cervical lym-
phadenopathy was present and a lumbar puncture for CSF
examination. Examinations of blood were performed only
if other assays failed to show trypanosomes. Patients were
considered to be in early stage if the CSF leukocyte count
was 1–5/mm3, or in late stage when CSF leukocyte count
was >5/mm3, and treatment was selected accordingly. 
Melarsoprol was used throughout the study period for
most adult patients with late-stage trypanosomiasis; a
small number were treated with eflornithine during clinical
trials of this drug. Until mid-1985, late-stage disease in
children was treated with trimelarsan. Later, trimelarsan
was no longer available, and melarsoprol was used for
children as well. From 1984 to 1988, half of melarsoprol-
treated patients also received prednisolone during a ran-
domized controlled trial (10); thereafter, prednisolone was
given to all melarsoprol-treated patients, except for brief
periods of drug shortage. Details of treatment schemes are
available in other publications (10–13), in which various
parts of the cohort of patients reviewed here were report-
ed. Most patients were given 2 or 3 series (separated by 1-
week drug-free intervals) of 3 or 4 daily injections of
intravenous melarsoprol at the full dosage (3.6 mg/kg, for
a maximum of 180 mg), depending on the CSF leukocyte
count. During shortages of pentamidine and suramin,
melarsoprol (1 series of 3 injections) was sometimes used
in the treatment of early-stage patients. From April 1996 to
December 2001, a trial of 3 regimens of melarsoprol took
place (14), and consenting patients were randomized to
receive either the conventional dosage (3 series of 3 injec-
tions of 3.6 mg/kg), a new regimen of 10 consecutive daily
injections of 2.16 mg/kg (15), or a regimen of 3 series of 3
injections in which an incremental dosage was used (1.8,
2.16, 2.52; then 2.52, 2.88, 3.24; then 3.6 mg/kg for the last
3 injections). Enrollment in the latter arm of the study was
terminated prematurely in December 1998 when a high
relapse rate became apparent (14).
After treatment, patients were followed up with lumbar
punctures every 6 months for 2 years. Most of the follow-
up lumbar punctures were performed at Nioki hospital; in
the earlier years, some of these were performed by mobile
teams during visits to disease-endemic villages. The
patients were asked to come back sooner if they experi-
enced symptoms compatible with a relapse (somnolence,
constant headaches). The decision to administer a second
treatment (and thus to consider this case as a relapse) was
left to the discretion of the attending physician, but most
fulfilled one of the following criteria: 1) trypanosomes
found in the CSF (or rarely in the blood or lymph node
aspirate); 2) CSF leukocyte count ≥50/mm3 and higher
than the previous determination; or 3) CSF leukocyte
count of 20 to 49/mm3, higher than the previous determi-
nation, with the presence of symptoms compatible with a
relapse. When in doubt, the lumbar puncture was repeated
1–2 months later. In practice, distinguishing a genuine
relapse from a reinfection is not possible, and we will use
“relapse” to designate both. The primary analysis of risk of
relapsing considered all relapses, regardless of the interval
since melarsoprol treatment; in a secondary analysis, only
relapses happening within 2 years of treatment were con-
sidered.
For each case, we collected data on age, sex, village of
residence, date of diagnosis, mode of diagnosis (lymph
node aspirate, blood examinations [wet smear, thick smear,
hematocrit centrifugation technique, or any combination
thereof], CSF examination), pretreatment CSF leukocyte
count, treatment given, encephalopathy or death during
treatment, and whether a diagnosis of relapse was made
during posttreatment follow-up. Few data were missing
with the exception of the village of residence (missing for
61 of 164 patients in 1982) and the precise age (unknown
for 1 child and 152 adults). The database did not include
information on each follow-up lumbar puncture, but only
on those which led to a diagnosis of relapse. Thus, to esti-
mate the frequency of relapses, we used as the denomina-
tors all patients who survived treatment.
Data were entered and verified on EpiInfo 6.04, and
analyzed with Stata 8.0 (Stata Corporation, College
Station, TX, USA). Proportions were compared with the χ2
test. CSF leukocyte counts that had a non-normal distribu-
tion were compared with rank sum tests. Multivariate
analysis was performed by logistic regression; variables
that enhanced the fit of the model at the 0.05 level by using
the likelihood ratio test were retained.
Results
Table 1 summarizes sociodemographic, clinical, and
biologic characteristics of all patients during each 4-year
period from 1982 until 2001. Several of the changes reflect
the more systematic case-finding by mobile teams in the
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patients with a normal CSF leukocyte count decreased
considerably, as did the proportion of patients with a posi-
tive lymph node aspirate, while the proportion of patients
with CSF trypanosomes increased. The higher proportion
of cases in women in the earlier years and subsequent
decrease can be explained by this factor (women partici-
pate more in case-finding surveys) as well as by a shift in
the distribution of cases, with a progressively higher pro-
portion of cases in inhabitants of Nioki town (due to more
men migrating out of villages, rural communities have
more women then men, but Nioki town does not). Changes
in the proportion of patients with trypanosomes in the
blood were less striking; because examinations of blood
were not conducted for all patients, these variations might
reflect changes in the propensity of clinicians to order such
assays.
Table 2 shows the same characteristics, but only for
patients who were treated with melarsoprol. Similar
changes in distribution of cases according to sex and area
of residence were seen. Even though 96% of these patients
were given melarsoprol because they had a CSF leukocyte
>5/mm3, a shift occurred over time towards more
advanced disease upon diagnosis in recent years, as evi-
denced by the decrease in the proportion with a positive
lymph node aspirate, an increase in the proportion with
CSF trypanosomes, and a doubling of the median CSF
leukocyte count. Treatment regimens varied considerably
over time. The proportion of patients given prednisolone
also increased after the randomized controlled trial was
conducted (10), and its results generalized; the proportion
of patients in whom a melarsoprol-induced encephalopa-
thy developed decreased to 2% in the last 4-year period.
The proportion of patients found to relapse, whether all
relapses were considered or only those occurring within 2
years of diagnosis, increased significantly during
1994–1997, but decreased to its previous level from 1998
to 2001.
The risk factors for postmelarsoprol relapses during
this 20-year period are shown in Table 3. Patients who died
during treatment were excluded. In univariate analyses,
relapses were significantly more common in male patients,
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from 1994 to 1997, and in patients treated with the incre-
mental dosage regimen; relapses were much less common
in patients from the Baboma/Basengele subdistrict. Table 3
also displays the results of the multivariate analysis.
Associations between relapses and male sex, CSF try-
panosomes, residence elsewhere than the Baboma/
Basengele subdistrict, and treatment with the incremental
dosage regimen were little altered by adjustment for con-
founding factors and remained statistically significant.
When results were adjusted for these confounders (espe-
cially treatment regimens), diagnosis from 1994 to 1997
was no longer associated with a higher probability of
relapse. The univariate association between CSF leukocyte
count and relapses was also strongly confounded by treat-
ment regimens. Removing from the analysis the small
number of patients with a normal pretreatment CSF leuko-
cyte count had no impact on any of the adjusted odds ratios
(data not shown).
Discussion
In the Nioki focus of DRC, the frequency of failure of
melarsoprol therapy among patients with late-stage T. b.
gambiense trypanosomiasis increased in 1994 to 1997 but
returned to its normal level in 1998 to 2001. This was driv-
en essentially by a high risk for relapse among patients
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regimen of incremental dosage of melarsoprol (14). The
risk for relapse decreased as soon as enrollment of patients
in this arm of the trial was terminated. This overall stabil-
ity in the frequency of postmelarsoprol relapses is remark-
able considering that over time the pretreatment
characteristics of patients changed in ways (a higher pro-
portion of cases among men, more patients with CSF try-
panosomes) that should normally have led to an increase in
the risk for relapse. These confounding factors and the oth-
erwise stable crude risk for relapse resulted in significant-
ly lower odds of relapse in patients treated in 1990 to 1993
and 1998 to 2001 compared to those treated at the begin-
ning of the study period. The crude risk for relapse among
patients treated in Nioki in 1998 to 2001 was similar to that
reported among patients treated in Léopoldville (Kinshasa)
50 years ago (16).
We did not have information on the completeness of
follow-up for each patient in the cohort. However, previ-
ous studies in Nioki in which this was measured have con-
sistently shown that >80% of patients were followed up for
>2 years after initial treatment (14,17). During the study
period, Nioki hospital was the only one in that part of DRC
to offer treatment with eflornithine to patients who
relapsed after treatment with melarsoprol. It thus seems
unlikely that relapses among our patients would have been
identified and managed by other healthcare providers.
Some relapsing patients might have died at home without
a diagnosis being made, but given the slow course of the
disease and the short distances to Nioki hospital, this situ-
ation probably did not occur very often. Thus, although
using as denominators all patients who survived melarso-
prol treatment might have somewhat underestimated the
true frequency of relapses, we think that this bias was not
substantial and probably did not change over time.
At least 3 factors that generally contribute to the emer-
gence of resistance to antimicrobial agents are not found in
the context of the treatment of African trypanosomiasis,
which probably explains the stable frequency of post-
melarsoprol relapses in Nioki over 2 decades. First, little
drug pressure exists: melarsoprol is not used to treat any
other condition, and supplies are controlled by a national
organization, according to the number of cases reported by
each health facility. Second, subtherapeutic doses have not
been administered on any sizeable scale; on the contrary,
most patients have probably been overtreated ever since
the drug became available (15,18). Third, little potential
exists for the preferential transmission of melarsoprol-
resistant strains because patients with relapses rarely har-
bor trypanosomes in the bloodstream or lymph nodes, only
in the CSF. Such patients are likely not very infectious.
As in Uganda and Angola (4,19), we found an associa-
tion between the presence of CSF trypanosomes and fail-
ure of melarsoprol. Given the limited CSF penetration of
melarsoprol, modest geographic variations in in vitro sus-
ceptibility might have an impact on the frequency of post-
melarsoprol relapses. Twenty-four hours after the
administration of melarsoprol, plasma levels are in the
range of 2-4 µg/mL, while CSF levels are much lower,
from 0.02 to 0.07 µg/mL(18,20,21). For 12 isolates of T.b.
gambiense from northwestern Uganda, the MIC of melar-
soprol was higher (0.009–0.072 µg/mL) than for 2 isolates
from Côte d’Ivoire (0.001–0.018 µg/mL); the higher MIC
of 0.072 µg/mL was superior to levels that can be expect-
ed in CSF (22). Fifty percent inhibitory concentrations
measured in T.b.  gambiense isolates from northwestern
Uganda were also higher than in isolates from Côte
d’Ivoire (23). In such circumstances, CSF concentrations
of melarsoprol might be insufficient to eliminate all para-
sites. So far, no evidence that genetically determined vari-
ations in drug pharmacokinetics might explain this
heterogeneity in the frequency of postmelarsoprol failures
(21,23). Within the Nioki focus, a lower risk for melarso-
prol failure in the Baboma/Basengele subdistrict has been
consistently noted for more than a decade (11); we specu-
late that this might reflect a limited exchange of try-
panosomes between the various foci, in which case the in
vitro susceptibility of the initial strain(s) in a given focus
would be maintained over the years.
Finally, our results suggest that variations in the regi-
mens of melarsoprol used in each country may also explain
some, but not all, of the high rates of postmelarsoprol fail-
ures in specific locations. Aregimen of incremental dosage
was indeed used in Uganda (4) and in some patients at
Kimpangu hospital, Zaire (24). Whether graded dosing
was used in Sudan is unclear. In Angola, the same regimen
(3 series of 4 injections: 1.2, 2.4, 3.6, 3.6 mg/kg for each
series) was used in M’banza Congo, where 25% of patients
relapsed (5), and in Dondo, where only 5%–6% of patients
relapsed (15,19). Unfortunately, melarsoprol MICs for
strains from the M’banza Congo focus have not yet been
measured, but trypanosomes from this focus are likely
intrinsically more resistant to melarsoprol than elsewhere. 
These findings, although reassuring, underline the
necessity of a strengthened surveillance system for African
trypanosomiasis, through which secular trends in the fre-
quency of treatment failures among patients with T.b. gam-
biense trypanosomiasis would be monitored in a small
number of sentinel centers. The World Health
Organization is developing such a system (25). Its meas-
ures will need to take into consideration modifications in
the baseline characteristics of patients (most of which will
be a result of changes in the intensity of case finding),
changes in therapeutic regimens, and the completeness of
follow-up by using Kaplan-Meier analyses. 
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